August 25, 2026 07:01 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Reservation for poor, not caste’: Stir at Delhi’s Jantar Mantar | Dalit woman 'gangrape-murder' shocker in Karnataka: 4 arrested after body found in well | India dismisses Pakistan's 'frustration' over US envoy's J&K remark | Centre denies US visit clearance to Telangana CM Revanth Reddy, says programmes 'not appropriate' | Delhi Police register FIR in pellet gun case after Rahul Gandhi's sit-in | Rahul Gandhi stages dharna at Delhi police station over CJP protest crackdown, targets Amit Shah | CJP school tour turns chaotic in Jaipur: Cars vandalised, stones pelted as Ashutosh Ranka alleges BJP ‘goons’ attack | Vande Mataram row: Kangana Ranaut slams Sharmila Tagore, says ‘come out of Hindu-Muslim mindset’ | Jadavpur erupts again: ABVP-SFI clash, police barricades shattered as fresh tension grips area | Ex-Congress MP and 1984 anti-Sikh riots convict Sajjan Kumar dies while serving life sentence

Lupin launches generic Aricept tablets in the US

| | Mar 31, 2016, at 09:23 pm
Mumbai/ Baltimore, Mar 31 (IBNS) Mumbai-based Lupin Limited (Lupin), a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally, announced on Thursday that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept® Tablets, 23mg.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. works in the area of generic medicines and branded formulations.
 
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept® Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type.
 
Aricept® had US sales of USD 47.1 million (IMS MAT December 2015).

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.